m

Eli Lilly's obesity drug notes 24.2% average weight loss

Eli Lilly's investigational obesity drug reduced phase 2 study participants' weight by 24.2 percent after nearly a year's worth of treatment, marking more significant weight loss results compared to other drugs currently being studied or on the market.

In a trial for retatrutide, the average study participant lost 17.5 percent of their weight after 24 weeks and 24.2 percent after 48 weeks, Eli Lilly said in a June 26 news release. A placebo and the medication were administered subcutaneously in 338 adults who are overweight with a weight-related condition, not including Type 2 diabetes, or obese.

In comparison, an experimental pill version of Novo Nordisk's Ozempic resulted in 15.1 percent weight loss in a phase 3 study, and an approved injectable drug for chronic weight management, Wegovy, trimmed the average person's weight by 12.4 percent. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like